

**DCAT**  
**TOP** ↑  
**Industry**  
**NEWS**

***BUSY WEEK?** Here are the  
**TOP INDUSTRY NEWS** stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

**1. [Teva Appoints New President and CEO](#)**

Teva Pharmaceutical Industries has appointed Kåre Schultz, former president and CEO of H. Lundbeck A/S, as its new president and CEO. Schultz takes charge amidst a major restructuring at Teva involving staff reductions of 7,000 employees and the closing or divesting of 15 manufacturing plants following disappointing second-quarter results in which Teva took a goodwill impairment charge of \$6.1 billion related to the performance of its US generics business. [Read More](#)

**2. [Dow Chemical, DuPont Complete Merger](#)**

Following the completion of the mega merger between The Dow Chemical Company and DuPont on August 31, 2017, the combined company, DowDuPont, has announced adjustments to the composition of three divisions that were formed following the completed transaction. The combined entity plans to separate each business into independent companies over the next 18 months. [Read More](#)

**3. [Congress Reviews User-Fee Program for OTC Drugs](#)**

The Subcommittee on Health of the US House of Representatives' House Energy & Commerce Committee held a hearing to examine draft legislation for establishing an over-the-counter (OTC) monograph user-fee program at the FDA. [Read More](#)

**4. [BMS Completes Acquisition of IFM Therapeutics](#)**

Bristol-Myers Squibb (BMS) has completed its previously announced acquisition of IFM Therapeutics, a company developing therapies to treat cancer, autoimmunity, and inflammatory disorders, in a deal worth up to \$2.3 billion. BMS first announced the acquisition in August 2017. [Read More](#)

**5. [Pfizer Receives FDA Warning Letter for EpiPen Injector Mfg](#)**

The FDA has issued a Warning Letter to Meridian Medical Technologies, a Pfizer subsidiary and Mylan's manufacturing partner for Mylan's EpiPen Auto-Injector (epinephrine injection, USP) products for GMP violations for combination products. The company was cited for both drug cGMP and quality-system deficiencies. [Read More](#)

**6. [Teva Sells Women's Health Product for \\$1.1 Billion](#)**

Teva Pharmaceutical Industries has agreed to sell its intrauterine copper contraceptive, Paragard, for \$1.1 billion to CooperSurgical, a Trumbull, Connecticut-headquartered medical equipment manufacturer focused on women's health. [Read More](#)

**7. [J&J Halts Development of Hepatitis C Drug Among Competition](#)**

Janssen Pharmaceuticals, part of Johnson & Johnson (J&J), has terminated its collaboration with Achillion Pharmaceuticals for developing an investigational hepatitis C treatment regimen of a combination of three direct acting antivirals due to the competition in the hepatitis C market. This is part of DCAT Value Chain Insights Pipeline News. [Read More](#)

**8. [Amgen, Allergan Get FDA OK for Biosimilar to Roche's Avastin](#)**

The FDA has approved Amgen's and Allergan's Mvasi (bevacizumab-awwb), a biosimilar to Roche's

cancer drug Avastin (bevacizumab). Avastin had 2016 global sales of CHF 6.78 billion (\$7.04 billion). This is part of *DCAT Value Chain Insights* Drug Approval News. [Read More](#)

## 9. [FDA Seeks Input on Continuous Manufacturing](#)

The FDA is inviting input through a public docket, open until September 21, 2017, on issues related to the adoption of continuous manufacturing in the pharmaceutical industry, which includes input on best practices for solid-dosage manufacturing. [Read More](#)

## 10. [ICH Finalizes Q&A Document on Starting Materials](#)

The International Council for Harmonization (ICH) moved forward a questions-and-answers guideline to help clarify issues when selecting and justifying starting materials for drug and biologic manufacturing. ICH brings together regulatory authorities and the pharmaceutical industry to discuss scientific and technical aspects of drug registration. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!***

### ***About Top Industry News***

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)